pharma · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu
Daihong Liu is a pharma organization headquartered in CN. Primary therapeutic focus areas include Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). NovaPharmaNews links 1 clinical program(s), 0 drug profi
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 8
- Patents
- 0
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
Phase 2 · small molecule · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) is a Phase 2 program (small_molecule) at Daihong Liu with 1 ClinicalTrials.gov record(s).
Internal code M2025-222-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Daihong Liu
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
- Status
- active
- Trials
- 1